LivaNova (LIVN) to Release Quarterly Earnings on Wednesday

LivaNova (NASDAQ:LIVN) will release its earnings data before the market opens on Wednesday, October 30th. Analysts expect LivaNova to post earnings of $0.71 per share for the quarter. LivaNova has set its FY 2024 guidance at 3.100-3.200 EPS and its FY24 guidance at $3.10-$3.20 EPS.Parties interested in listening to the company’s conference call can do so using this link.

LivaNova (NASDAQ:LIVN) last announced its quarterly earnings results on Wednesday, July 31st. The company reported $0.81 EPS for the quarter, topping the consensus estimate of $0.66 by $0.15. LivaNova had a negative net margin of 1.37% and a positive return on equity of 13.77%. The business had revenue of $318.60 million for the quarter, compared to analysts’ expectations of $305.05 million. On average, analysts expect LivaNova to post $3 EPS for the current fiscal year and $3 EPS for the next fiscal year.

LivaNova Stock Up 1.1 %

LIVN opened at $53.33 on Wednesday. LivaNova has a 52 week low of $42.75 and a 52 week high of $64.47. The company has a quick ratio of 2.94, a current ratio of 3.45 and a debt-to-equity ratio of 0.49. The firm has a 50-day simple moving average of $50.12 and a two-hundred day simple moving average of $53.22. The company has a market capitalization of $2.89 billion, a PE ratio of -88.88 and a beta of 1.00.

Analyst Upgrades and Downgrades

LIVN has been the subject of a number of analyst reports. Needham & Company LLC increased their price target on shares of LivaNova from $72.00 to $75.00 and gave the company a “buy” rating in a report on Wednesday, July 31st. Robert W. Baird raised LivaNova from a “neutral” rating to an “outperform” rating and raised their price objective for the company from $55.00 to $66.00 in a research note on Tuesday, September 17th. Baird R W raised LivaNova from a “hold” rating to a “strong-buy” rating in a research report on Tuesday, September 17th. The Goldman Sachs Group began coverage on LivaNova in a research report on Friday, October 4th. They issued a “buy” rating and a $65.00 price target for the company. Finally, Stifel Nicolaus boosted their price objective on shares of LivaNova from $70.00 to $72.00 and gave the company a “buy” rating in a research report on Thursday, July 25th. One investment analyst has rated the stock with a hold rating, six have given a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat, LivaNova has an average rating of “Buy” and an average price target of $69.83.

LivaNova Company Profile

LivaNova PLC, a medical device company, designs, develops, manufactures, and sells therapeutic solutions worldwide. The company operates through Cardiopulmonary, Neuromodulation, and Advanced Circulatory Support segments. The Cardiopulmonary segment develops, produces, and sells cardiopulmonary products, including oxygenators, heart-lung machines, autotransfusion systems, perfusion tubing systems, cannulae, connect, and other related products.